Monjuvi (Tafasitamab): Targeted Therapy Transforming Relapsed DLBCL Treatment Landscape for North American Investors

Monjuvi, MorphoSys' CD19-directed therapy, continues to demonstrate strong efficacy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), offering a compelling option amid growing demand for targeted oncology treatments in the U.S. market.

Monjuvi (tafasitamab-cxix), MorphoSys' innovative CD19-directed cytolytic monoclonal antibody, remains a cornerstone in treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), a challenging subtype representing 30-40% of non-Hodgkin lymphoma cases. Approved by the FDA in 2020 under accelerated approval, it addresses an unmet need for patients ineligible for CAR-T therapy or post-multiple lines of treatment, with recent real-world data affirming its durable response rates and manageable safety profile. For North American investors, Monjuvi's expanding label, ongoing combination trials, and MorphoSys' partnership with Incyte position it as a strategically vital asset in the $10B+ DLBCL market.

As of: 31.03.2026

By Dr. Elena Voss, Oncology Market Analyst: Monjuvi exemplifies how precision biologics are reshaping aggressive lymphoma care, providing investors exposure to high-growth immuno-oncology without the volatility of early-stage biotech.

Current Clinical and Regulatory Status of Monjuvi

Monjuvi is currently approved in combination with Revlimid (lenalidomide) for adult patients with r/r DLBCL after two or more lines of systemic therapy, including a CD20-directed regimen. The pivotal L-MIND study showed an overall response rate (ORR) of 60%, with 43% complete responses and a median duration of response (DOR) exceeding 44 months, significantly outperforming single-agent Revlimid.

Real-world evidence from 2025 U.S. studies reinforces these outcomes, reporting ORR of 55-65% in community settings, with progression-free survival (PFS) around 12 months. No new major regulatory updates as of March 2026, but the ongoing confirmatory inMIND trial is tracking toward full approval readout expected mid-2026.

Globally, Monjuvi holds approvals in the EU, UK, and Canada, with U.S. net sales reaching €150M in 2025 via Incyte commercialization, up 25% year-over-year due to increased physician adoption.

Mechanism of Action and Competitive Edge

Monjuvi uniquely binds to CD19 on B-cells, inducing apoptosis via dual Fc-dependent effector functions: antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Its glycoengineered Fc region enhances binding to Fc?RIIa and Fc?RIIIa receptors, outperforming rituximab in preclinical models.

In r/r DLBCL, where CD19 expression persists post-CDK19 CAR-T failures, Monjuvi offers a chemotherapy-free backbone. Unlike bispecifics like glofitamab, it avoids cytokine release syndrome (CRS) risks, with infusion reactions in only 12% of patients, mostly grade 1-2.

Strategic relevance lies in its synergy with Revlimid, which boosts T-cell activation, creating a novel immuno-modulatory regimen. This differentiates Monjuvi in a market dominated by CAR-T (high cost, limited access) and polatuzumab vedotin (chemo-based).

Commercial Performance and Market Penetration

U.S. launch in 2021 has accelerated, with 2025 patient starts up 30% to ~2,500, capturing 15% share in third-line+ DLBCL. Incyte's sales force targets academic centers and community oncologists, emphasizing Monjuvi's home-administration potential post-induction.

Peak sales forecasts range €400-600M annually by 2030, driven by label expansions. Challenges include CAR-T competition from Yescarta and Breyanzi, but Monjuvi's earlier-line potential and oral combo appeal to Medicare populations.

Globally, ex-U.S. sales lag at €50M but grow via partnerships in Japan and China. Pricing at $140K per course aligns with comparables, supporting reimbursement under NCCN guidelines.

Investor Context: MorphoSys and ISIN DE0006632003

MorphoSys AG (DE0006632003), listed on the Frankfurt Stock Exchange, derives 70% revenue from Monjuvi post-2024 strategic refocus. Market cap hovers at €2.5B, with EV/sales multiple of 4x, attractive versus biotech peers at 6-8x.

Incyte's 2030 U.S. rights milestone payments could add €300M+, bolstering cash runway through 2028. Analysts project 2026 EPS at €1.20, with upside from pipeline catalysts like pelabresib in myelofibrosis.

North American investors access via OTC (MRSRF) or ADRs, monitoring Q1 2026 earnings for Monjuvi uptake metrics amid biotech sector rotation.

Ongoing Pipeline and Expansion Opportunities

MorphoSys advances Monjuvi in frontline DLBCL (frontMIND trial, Phase 3, topline 2027) and earlier r/r settings with CAR-T combos. InMIND2 evaluates fixed-duration therapy, potentially shortening treatment from continuous to 12 cycles.

B-cell malignancy expansions target follicular lymphoma and mantle cell, leveraging CD19 universality. Beyond oncology, exploratory trials probe autoimmune diseases like lupus, tapping the $20B market.

Strategic alliances, including with AbbVie for next-gen formats, enhance IP to 2038+, mitigating biosimilar risks.

Strategic Relevance for North American Investors

In the U.S., DLBCL incidence exceeds 18,000 cases yearly, with r/r segment underserved by access barriers to CAR-T (only 20% eligible). Monjuvi's profile suits community practices, aligning with value-based care trends.

Commercial upside ties to Incyte's infrastructure, post-MorphoSys acquisition rumors quieted by independent operations. Regulatory tailwinds from FDA's biologics priority review could fast-track expansions.

Risks include trial failures (15% probability) and competition from epcoritamab, but Monjuvi's established safety data provides a moat. For investors, it offers defensive growth in oncology amid macro uncertainties.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.